Login to Your Account



Medivation Cleared to Begin Pivotal Prostate Cancer Trial

By Jennifer Boggs


Thursday, March 19, 2009
Well under way with pivotal trials of Alzheimer's disease drug Dimebon, Medivation Inc. is moving into late-stage development with another product, MDV3100, an androgen receptor antagonist, in prostate cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription